Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration

International Journal of Antimicrobial Agents

Volumn 42, Issue 4, 2013, Pages 335-342

  Malone, Maeve E ^a   Corrigan, Owen I ^a   Kavanagh, Pierce V ^b   Gowing, Caitriona ^c   Donnelly, Maria ^c   D'Arcy, Deirdre M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Amphotericin B lipid complex; Continuous venovenous haemodiafiltration; Critical illness; Intensive care; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PUMP; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTINUOUS HEMODIAFILTRATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; STEADY STATE; THERAPY EFFECT; TIME TO TREATMENT; TISSUE DISTRIBUTION;

AMPHOTERICIN B LIPID COMPLEX; CONTINUOUS VENOVENOUS HAEMODIAFILTRATION; CRITICAL ILLNESS; INTENSIVE CARE; PHARMACOKINETICS;

AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CRITICAL ILLNESS; FEMALE; HALF-LIFE; HEMODIAFILTRATION; HUMANS; MALE; MIDDLE AGED; PLASMA;

EID: 84884704370     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.06.011     Document Type: Article

References (16)

1. C. Lass-Flörl, M.C. Arendrup, J.L. Rodriguez-Tudela, M. Cuenca-Estrella, P. Donnelly, and W. Hope European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing, EUCAST technical note on amphotericin B Clin Microbiol Infect 17 2011 E27 E29
2. A.M. Tortorano, J. Peman, H. Bernhardt, L. Klingspor, C.C. Kibbler, and O. Faure Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study Eur J Clin Microbiol Infect Dis 23 2004 317 322
3. J.J. Torrado, R. Espada, M.P. Ballesteros, and S. Torrado-Santiago Amphotericin B formulations and drug targeting J Pharm Sci 97 2008 2405 2425
4. V.L. Kan, J.E. Bennett, M.A. Amantea, M.C. Smolskis, E. McManus, and D.M. Grasela Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers J Infect Dis 164 1991 418 421
5. S.J. Olsen, M.R. Swerdel, B. Blue, J.M. Clark, and D.P. Bonner Tissue distribution of amphotericin B lipid complex in laboratory animals J Pharm Pharmacol 43 1991 831 835
6. I. Bekersky, R.M. Fielding, D.E. Dressler, J.W. Lee, D.N. Buell, and T.J. Walsh Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans Antimicrob Agents Chemother 46 2002 828 833
7. R. Bellmann, P. Egger, A. Djanani, and C.J. Wiedermann Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration Int J Antimicrob Agents 23 2004 80 83
8. A. Adedoyin, J.F. Bernardo, C.E. Swenson, L.E. Bolsack, G. Horwith, and S. DeWit Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies Antimicrob Agents Chemother 41 1997 2201 2208
9. A. Adedoyin, C.E. Swenson, L.E. Bolcsak, A. Hellmann, D. Radowska, and G. Horwith A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections Antimicrob Agents Chemother 44 2000 2900 2902
10. T.J. Walsh, P. Whitcomb, S. Piscitelli, W.D. Figg, S. Hill, and S.J. Chanock Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis Antimicrob Agents Chemother 41 1997 1944 1948
11. S. Weiler, H. Vogelsinger, M. Joannidis, S. Dunzendorfer, and R. Bellmann Influence of albumin dialysis on pharmacokinetics of amphotericin B colloidal dispersion and amphotericin B lipid complex Artif Organs 35 2011 667 671
12. F. Pea, P. Viale, F. Pavan, and M. Furlanut Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy Clin Pharmacokinet 46 2007 997 1038
13. I. Bekersky, R.M. Fielding, D.E. Dressler, J.W. Lee, D.N. Buell, and T.J. Walsh Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate Antimicrob Agents Chemother 46 2002 834 840
14. WinNonlin® version 5.2. Noncompartmental analysis output parameters and their computation formulas. St Louis, MO: Pharsight Corp.
15. M. Rowland, and T.N. Tozer Disease Clinical pharmacokinetics and pharmacodynamics: concepts and applications 4th ed. 2010 Lippincott Williams and Wilkins Baltimore, MD 425 434
16. B.A. Boucher, G.C. Wood, and J.M. Swanson Pharmacokinetic changes in critical illness Crit Care Clin 22 2006 255 271